Abstract-The synthesis of imidazolidin-4-one derivatives of primaquine as potential antimalarial agents is described. The target compounds were synthesized in three steps: (i) condensation of (^)-primaquine with N a -protected amino acids, (ii) removal of the N aprotecting group, and (iii) reaction of the N-acylprimaquine with a carbonyl compound: acetone, three cyclic ketones and veratraldehyde. Using 2-formylbenzoic acid in the third step afforded 1H-imidazo[2,1-a]isoindole-2,5(3H,9bH)-diones. All products were isolated in good to excellent yields. Whereas imidazolidin-4-ones were formed as mixtures of all possible diastereomers in equal amounts, 1H-imidazo[2,1-a]isoindole-2,5(3H,9bH)-diones were produced in a stereoselective fashion. The compounds hydrolyse very slowly (t 1/2 5-30 d) in pH 7.4 buffer to release primaquine. These primaquine derivatives are being submitted to biological assays, and preliminary results of their antimalarial activity are quite encouraging. q
Introduction
Primaquine, 1, is the only currently available drug that is active against both the latent liver forms of the relapsing malaria caused by Plasmodium vivax and Plasmodium ovale 1 and the gametocytes from all species of parasite causing human malaria, including chloroquine-resistant Plasmodium falciparum. 2 However, the clinical use of primaquine is impaired as a result of a rapid metabolic inactivation to form carboxyprimaquine 2, 3 -6 and to serious blood toxicity, particularly the ability to induce oxidation of oxyhemoglobin to methemoglobin. 7 Several peptide and amino acid derivatives of primaquine, for example, 3, have been prepared to reduce toxicity of the parent as well as to reduce the oxidative deamination metabolic pathway leading to 2. 8 -11 Despite the improved activity/toxicity ratio usually displayed by 3, most of these derivatives are rapidly hydrolysed to primaquine by aminopeptidases and endopeptidases, 11, 12 suggesting that they might undergo extensive hydrolysis to the parent drug in the intestinal lumen when given orally. Thus, the design of orally effective and metabolically stable derivatives of the antimalarial agents 3 is of obvious interest.
Replacement of an amide bond with appropriate isosteres is a commonly used lead-optimization strategy for enhancing enzymatic stability of a peptide. 13 Alternatively, the peptide drug can be converted into a prodrug or transport form that 0040 Abbreviations: AA, amino acid; HAAPQ, amino acid derivative of primaquine (unprotected); Ala, alanine residue; Boc, tert-butyloxycarbonyl (protecting group); BocAAOH, N a -Boc-protected amino acid; BocAAPQ, N a -Boc-protected amino acid derivative of primaquine; bs, broad singlet; Bzl, benzyl; CDCl 3 , deuterated chloroform; d, doublet; dd, double doublet; dt, double triplet; d, chemical shift (in ppm); DCCI, N,N 0 -dicyclohexylcarbodiimide; DCM, dichloromethane; DCU, N,N 0 -dicyclohexylurea; DHB, 2,5-dihydroxybenzoic acid; DIEA, diisopropylethylamine; DIPCDI, N,N 0 -diisopropylcarbodiimide; DIU, N,N 0 -diisopropylurea; Gly, glycine residue; HOBt, N-hydroxybenzotriazole; i Bu, isobutyl;
i Pr, isopropyl; Leu, leucine residue; m, unresolved multiplet; MALDI-TOF, matrix-assisted laser desorption ionization-time-of-flight; NOE, nuclear Overhauser effect; PES, potential energy surface; Phe, phenylalanine residue; ppm, parts per million (NMR chemical shift unit); PQ, primaquine; q, quartet; s, singlet; t, triplet; TEA, triethylamine; THF, tetrahydrofuran; TLC, thin layer chromatography; TMS, tetramethylsilane; Val, valine residue.
protects the parent peptide against proteolytic degradation at the mucosal absorption barrier or in the blood.
14 Such a prodrug must be capable of reverting to the parent peptide drug following oral absorption via an unspecific plasma enzyme-catalysed reaction or a non-enzymatic pathway. Imidazolidin-4-one, 4, formation was introduced as a useful prodrug approach to protect the N-terminal amino acid residue of di-, tri-and pentapeptides against Scheme 1.
Scheme 2. (i) DCCI, HOBt, BocAAOH; (ii) (1) TFA, (2) Na 2 CO 3 ; (iii) Me 2 CO or C 5 , C 6 or C 7 cyclic ketones or 3,4-(MeO) 2 -C 6 H 3 CHO in refluxing MeOH, TEA, molecular sieves.
aminopeptidase-catalysed hydrolysis (Scheme 1). 15 -18 The synthetic approaches for the preparation of imidazolidin-4-ones involve the reaction of the peptide with an aldehyde or ketone followed by intramolecular cyclization. This reaction is catalysed by acids 19 or bases 20 although no catalyst is needed with acetone. 21 Usually, peptide imidazolidin-4-one derivatives, 4, were quantitatively hydrolysed to the parent peptide in physiological conditions (pH 7.4 buffer at 37 8C) with half-lives ranging from in 1 to 30 h, depending on the N-terminal dipeptide sequence and on the R 3 , R 4 imidazolidinone substituents (Scheme 1). 15 -18 The same imidazolidin-4-one strategy was used to improve the bioavailability of ampicillin, a b-lactam that also contains a peptide backbone. 22 The corresponding imidazolidin-4-one, hetacillin, is also rapidly hydrolysed to ampicillin in physiological conditions.
Here we report the synthesis of compounds 5, incorporating the imidazolidin-4-one scaffold, as potential peptidasestable prodrugs of amino acid derivatives of primaquine, 3 (Scheme 2). As the primaquine starting material was a racemate, the cyclization reactions of 3 with ketones or aldehydes yielded compounds 5 as the corresponding diastereomeric mixtures. Reaction of 3 with 2-formylbenzoic acid leads to 1H-imidazo[2,1-a]isoindole-2,5(3H,9bH)-dione production, 6, via a diastereoselective cyclization (Scheme 3).
Results and discussion

Synthesis of N-a-aminoacylprimaquine derivatives
The target imidazolidin-4-ones 5 were synthesised via the corresponding amino acid derivatives 3 (Scheme 2). The Boc-protected amino acid intermediates 7 were prepared using standard peptide coupling methods 23 that involved N a -Boc protected amino acid (BocAAOH) coupling to (^)-primaquine (PQ), using either dicyclohexylcarbodiimide (DCCI) 24 or diisopropylcarbodiimide (DIPCDI) 25 in combination with the auxiliary nucleophile 1-hydroxybenzotriazole (HOBt). 26 Products 7b -e were isolated as mixtures of the two possible diastereomers ( 13 C NMR signal duplications were observed), even though they could not be distinguished by the chromatographic techniques employed. The N a -Boc-protected amino acid derivatives of primaquine, 7a-e, were treated with neat trifluoroacetic acid (TFA) to remove the Boc-protecting group. 27 After neutralization of the resulting trifluoroacetates with aqueous sodium carbonate, the deprotected amino acid derivatives of primaquine (HAAPQ, 3) were extracted with chloroform and isolated as yellow-orange waxy oils in 83 -97% yields. All HAAPQ derivatives, 3a -e, were characterized by NMR and MALDI-TOF-MS.
Reaction of the N-a-aminoacylprimaquine derivatives with carbonyl compounds
The HAAPQ intermediates, 3a -e, reacted with acetone, cyclopentanone, cyclohexanone and cycloheptanone, by refluxing both reactants in methanol in the presence of triethylamine (TEA), 4 Å molecular sieves and an excess of the ketone, to form the expected imidazolidin-4-ones, 5, in good yields (44 -81%). When the reaction of 3 with ketones was carried out without TEA or 4 Å molecular sieves (or both) only small amounts of condensation products 5 were isolated. The imidazolidin-4-ones 5, containing a chiral amino acid residue (e.g., 5b-e, derived from Ala, Val, Leu and Phe, respectively) were isolated as mixtures of two co-eluting diastereomers, as detected by the duplication of some 13 C NMR signals. For example, compound 5c derived from HValPQ, 3c, and acetone presented two signals for the following resonances: C-2, C-5 and C-6 in the quinoline ring; C-1 0 , C-2 0 , C-3 0 and C-4 0 in the amine side-chain; C-2 and C-4 in the imidazolidin-4-one ring.
All HAAPQ derivatives, 3, were also reacted with formaldehyde and ethyl glyoxylate, but, unfortunately, only untractable mixtures were obtained. In constrast, reaction of compounds 3b -e with veratraldehyde (3,4-dimethoxybenzaldehyde) as described above, afforded the corresponding imidazolidin-4-ones 5u -x with global yields of 57 -94%. The imidazolidin-4-one derived from HGlyPQ, 3a, was probably formed, since the correct molecular weight was detected by MALDI-TOF-MS analysis of the crude mixture. However, this compound was too unstable to be satisfactorily isolated and characterized by NMR.
The cyclization of 3b -e with aldehydes generates a new chiral centre, so four imidazolidin-4-one diastereomeric pairs are to be expected. In fact, TLC monitoring could distinguish one to four spots in the reaction of veratraldehyde with compounds 3b-e. The closeness between the R f values for the different diastereomers was obviously high, depending on the amino acid involved. Best chromatographic resolution was found for the Phe-derived product 5x (all four spots, though close, could be distinguished), whereas for the Leu-derived compound 5y a single fraction was obtained. Interestingly, the 1 H NMR spectra of 5y presented four well-resolved and equally intense signals at 5.12, 5.20, 5.25 and 5.31 ppm, corresponding to the imidazolidinone NCHN resonance, suggesting that equal amounts of all four diastereomers were formed. In contrast, it was possible to isolate two pure diastereomers of 5x, each one presenting a singlet at ca. 5.1 ppm, corresponding to the imidazolidinone NCHN resonance, and three singlets at 3.7 -3.9 ppm, corresponding to each of the CH 3 O resonances. In addition, a 1:1 mixture of the other two diastereomers of 5x was also isolated, as indicated by the two equally intense singlets at ca. 5.0 ppm and six singlets in the 3.7-3.9 ppm region. The compounds derived from alanine, 5v, and valine, 5w, had an intermediate behaviour: two fractions could be isolated in both cases, each of which corresponded to different combinations of the four diastereomers.
The reactions of compounds 3a -e with 2-formylbenzoic acid afforded the corresponding 1H-imidazo[2,1-a]isoindole-2,5(3H,9bH)-diones, 6a -e in good yields (44 -60%). Mass spectrometric analysis of crude 6e exhibited a signal at m/z¼538.6 corresponding to the imidazolidin-4-one intermediate that is formed prior to the cyclization that leads to the formation of the isoindole ring. The structural assignment of compounds 6 is based on spectroscopic data. For the glycine derivative 6a, two diastereomeric pairs of enantiomers were to be expected, and it was indeed possible to separately isolate two fractions from the reaction of 3a and 2-formylbenzoic acid. A characteristic feature of the 1 H NMR spectrum of each enantiomeric pair of 6a is the resonance of the NCHN group, which appears as a singlet at 5.6-5.8 ppm. Moreover, the glycine CH 2 signal appears as two doublets with typical geminal coupling constants ( 2 J¼11.7 Hz), reflecting the diastereotopic nature of the methylene protons. In contrast, compounds 6b -e were formed as mixtures of nonisolable diastereomers. However, the following 1 H and 13 C NMR data suggest the formation of only two diastereomers in each case, even though a total of four was anticipated. First, the resonance of the NCHN proton (H 9b ) appears as two 1:1 singlets at 5.7 -5.9 ppm. Second, the 13 C NMR spectra of 6b -e presented duplication for, among others: the C-5 and C-7 quinoline carbons; the C-1 0 , C-2 0 , C-3 0 and C-4 0 amine side-chain carbons; and the C-2, C-3 and C-5 atoms
In order to determine the absolute configuration of the new chiral center in 6b -e we carried out NOE experiments. For compound 6c, irradiation of C 9b -H of each diastereomer led to a clear positive NOE-effect for the C 3 -H ( Fig. 1 ) and for one of the methyls in the isopropyl side chain. In contrast, no significant effect was observed for hydrogen (CH 3 ) 2 CH in the same group upon irradiation of C 9b -H. Similar results were obtained for 6b and 6d: irradiation of C 9b -H of each 6b diastereomer caused a positive NOE for the C 3 -H and had no effect on the hydrogen atoms of the CH 3 ; irradiation of the C 9b proton in compound 6d caused positive NOEs on C 3 -H and (CH 3 ) 2 CHCH 2 , but no effect 28 The cause of such difference is not clear. The reaction path leading to 1H-imidazo[2,1-a]isoindole-2,5(3H,9bH)-diones is essentially the same as for imidazolidin-4-ones, that is, imine formation followed by intramolecular cyclization to the imidazolidinone structure, including an additional step for the intramolecular amide bond formation that generates the final pyrrolidinone structure. A possible explanation is that the o-carboxyl substituent in 2-formylbenzoic acid could establish a hydrogen bond with the amide group, yielding a rigid conformation that would constrain the stereochemistry of the subsequent intramolecular cyclization step. The lack of any such constraint in veratraldehyde would explain its different behaviour. To evaluate the validity of this hypothesis, we have performed semi-empirical calculations at the AM1 level 29 to optimise the geometry of the imine intermediate formed upon reaction with 2-formylbenzoic acid. The simplest chiral amino acid, alanine, was considered, and the calculations yielded the optimised structure depicted in Figure 2 . This structure clearly shows three intramolecular hydrogen bonds that stabilize the folding of the imine and favours a stereo-controlled cyclization. This leads to a final 1H-imidazo[2,1-a]isoindole-2,5(3H,9bH)-dione structure where atoms C 3 -H and C 9b -H are cis-oriented, which is in agreement with the NOE experiments. A final confirmation of this rationale could be given by X-ray diffraction experiments. Unfortunately, compounds 6 are all oils and all attempts to obtain crystals have been unsuccessful.
In vitro assessment of imidazolidin-4-ones 5 as potential prodrugs
The reactivity of several imidazolidin-4-ones 5 derived from ketones in pH 7.4 phosphate buffer at 37 8C was assessed by HPLC. Quite surprisingly, compounds 5 hydrolyse very slowly, though quantitatively, to the corresponding amino acid derivative 3 (Table 1 ). This behaviour contrasts with the rapid hydrolysis of their counterparts 4 derived from a dipeptide framework. For example the 2,2-dimethylimidazolidin-4-one 5a, derived from HGlyPQ, 3a, is hydrolysed ca. 100 times slower than their counterparts 4 derived from Gly-Phe or Gly-Tyr. 16 The same trend is observed when comparing derivatives 5 with imidazolidin-4-ones derived from higher peptides. For example, compound 5e derived from HPhePQ, 3e, is hydrolysed 60 times slower than the Leu-enkephalin derivative 8. 17 The rates of hydrolysis of 5 are largely affected by the substituents at C-2 of the imidazolidin-4-one moiety, with those derived from cyclopentanone, 5h and 5j, being significantly more reactive than those derived from acetone or cyclohexanone. Unfortunately, derivatives 5 derived from cycloheptanone displayed very low aqueous solubility precluding their study in the pH 7.4 phosphate buffer. The results presented herein indicate that imidazolidin-4-ones 5 will likewise hydrolyse slowly in vivo and thus can be considered as slow-release systems of the amino acid derivatives of primaquine.
Conclusion
In summary, amino acid derivatives, 3, of primaquine can be converted to the corresponding imidazolidin-4-ones 5 in good yields by reaction with both cyclic and acyclic ketones and aromatic aldehydes. Cyclization of 3 with an unsymmetrical carbonyl (veratraldehyde) yields mixtures of all four possible stereomers. However, when cyclization was carried out with an o-carboxylated aldehyde, diastereoselectivity was encountered, since only two out of four possible stereomers of the corresponding 1H-imidazo[2,1-a]isoindole-2,5(3H,9bH)-diones 6 were formed. The low rates of hydrolysis of imidazolidin-4-ones 5 in physiological conditions suggest that they may be useful as slow-release forms of the parent amino acid derivatives 3.
Experimental
General details
N a -Protected amino acids were purchased from NovaBiochem (Switzerland). Solvents were of p.a. quality and bought from Merck (Germany). Both thin layer chromatography (TLC) aluminium foil plates covered with silica 60 F 254 (0.25 mm) and silica-gel 60 (70 -230 mesh ASTM) for preparative column chromatography were also purchased from Merck. When required, solvents were previously dried with pre-activated molecular sieves (4 Å ) (Merck). Other chemicals were obtained from SigmaAldrich.
NMR spectra of compounds dissolved in deuterated chloroform (CDCl 3 ), containing tetramethylsilane (TMS) as internal reference, were acquired on a Bruker AMX-300 spectrometer. Mass spectrometry (MS) was performed by the matrix-assisted laser desorption ionization-time-offlight (MALDI-TOF) technique on an Applied Biosystems was suspended in dichloromethane (DCM, 30 mL), TEA (14 mmol) was added and the mixture was stirred in an icewater -NaCl bath for 30 min. After addition of the BocAAOH (3.3 mmol) and HOBt (4.0 mmol), the carbodiimide (DCCI or DIPCDI, 4.0 mmol) was slowly added to the mixture, which was kept at 0 8C for 2 h more. The reaction was allowed to proceed at room temperature for 2 d, with periodic monitoring by TLC. A second stepwise addition of carbodiimide (4.0 mmol) was made, and the reaction prolonged for a further 3 d. The solid phase formed was removed by suction filtration and identified as the carbodiimide-derived urea (DCU or DIU). The filtrate was evaporated to dryness and the residue dissolved in the minimum amount of warm acetone; the resulting solution was stored overnight at 4 8C and the urea precipitated was again removed by suction filtration. The filtrate was evaporated to dryness and the residue submitted to column chromatography on silica-gel, using DCM/acetone mixtures as eluents (in the proportions of 5:1 for compounds 7a-c and 10:1 for compounds 7d -e). Products 7a -e were isolated as yellow-orange oils in 78 -93% yields and successfully characterized by high-resolution MS and NMR, as detailed below. 
Acidic removal of the N a -Boc protecting groupsynthesis of compounds 3a -e
Compounds 7a -e were dissolved in a small volume of neat trifluoroacetic acid (TFA, ca. 5 mL) and the deprotection reactions allowed to proceed for 1-2 h at room temperature. Excess TFA was neutralized by dropwise addition of aqueous Na 2 CO 3 at 30% until pH 10; the supernatant oily phase formed in this process was extracted seven times with 10-mL portions of chloroform and the organic phases pooled, dried over anhydrous MgSO 4 and evaporated to dryness. Products 3a -e were thus isolated as yellow-orange oils in 83 -97% yields and successfully characterized by high-resolution MS and NMR, as detailed below. 
N-{4-[(6-Methoxyquinolin-8-yl)amino]pentyl}-2-aminoacetamide (3a
Reaction of 3a-e with symmetrical ketones: synthesis of imidazolidin-4-ones 5a -t
Compounds 3a-e (2 mmol) were mixed with an excess (4 mmol) of the appropriate ketone (acetone, cyclopentanone, cyclohexanone or cycloheptanone) and TEA (2 mmol) in dry methanol (10 mL) and the mixture refluxed for 3 d in the presence of 4 Å molecular sieves (1 g). The reaction was monitored by TLC and ketone was re-added (2 mmol) once per day. The molecular sieves were removed by decantation and the solution evaporated to dryness. The oily residue was submitted to column chromatography on silica-gel, eluted with DCM/THF (varying solvent proportions) or, for compound 5a, DCM/ethanol 15:1 (v/v). Fractions containing the chromatographically homogeneous product were pooled and evaporated to dryness, yielding 5a-t as yellow-orange oils (44 -81%) that were analyzed by high-resolution MS and NMR, as detailed below. 
Reaction of compounds 3a -e with veratraldehydesynthesis of imidazolidin-4-ones 5u-x
Compounds 3a -e (2 mmol) were mixed with a small excess (2.2 mmol) of veratraldehyde and TEA (2 mmol) in dry methanol (10 mL). The mixture was refluxed for 3 d in the presence of 4 Å molecular sieves (1 g) with periodic monitoring by TLC. One to four new TLC spots could be detected in the different reaction mixtures. The molecular sieves were removed by decantation and the solution evaporated to dryness. The oily residue was submitted to column chromatography on silica-gel, eluted with DCM/ THF (varying solvent proportions). Chromatographically homogeneous fractions were pooled and evaporated to dryness, yielding different combinations of the four possible diastereomers for each one of the imidazolidin-4-ones 5u -x. Global yields ranged from 57 to 95%. The different fractions of 5u -x were analyzed by MALDI-TOF MS and NMR, and spectral data are detailed below. The product derived from glycine could not be isolated and further characterized by NMR, but the expected molecular weight Compounds 3a -e (2 mmol) were mixed with a small excess of 2-formylbenzoic acid (2.2 mmol) and TEA (2 mmol) in dry methanol (10 mL). The mixture was refluxed for 3 d in the presence of 4 Å molecular sieves (1 g) with periodic monitoring by TLC. In the syntheses of compounds 6b -d only one new spot could be detected in the reaction mixtures, whereas two spots could be distinguished in the reaction mixtures for the syntheses of 6a and 6e. Molecular sieves were removed by decantation and the solution evaporated to dryness. The oily residue was submitted to column chromatography on silica-gel, eluted with DCM/ THF (varying solvent proportions). Chromatographically homogeneous fractions were pooled, evaporated to dryness and analyzed by NMR and MALDI-TOF MS. Global yields ranged from 44 to 60% and compounds 6b -e were found to be mixtures of two diastereomers (NMR), whereas it was possible to isolate each of the two diastereomers of 6a. In the purification of compound 6e, a second fraction of impure product was collected and analyzed by MALDI-TOF MS, showing the presence of an m/z peak (538.34) compatible with the imidazolidin-4-one structure (Calcd, 538.26).
